Takeda Says USPTO Shorted Life Of Patent For Diabetes Drugs
The U.S. Patent and Trademark Office did not sufficiently extend the life of a patent related to treatments for diabetes after prolonging consideration of Takeda Pharmaceutical Co. Ltd.'s patent application, the...To view the full article, register now.
Already a subscriber? Click here to view full article